Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The key drugs in the weight-loss injection market are ... US rival Eli Lilly has also recently gained attention with its dual ...

Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as “an extensive pipeline of ...

Eli Lilly saw Mounjaro sales climb by about 114% year ... Considering that GLP-1 drugs currently require a regular injection, it's likely many patients will opt for a straightforward pill option ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Elon Musk has publically favored Eli Lilly’s weight loss drug, Mounjaro, over Novo Nordisk ... Drug Authority for its insulin glargine injection. This approval marks a milestone in providing ...

Imagine this: You walk into your doctor and get your yearly flu vaccine and a yearly dose of your weight-loss injection. If Eli Lilly has its ... "weight-loss" shots: Mounjaro, prescribed for ...